SEM examination on corneal epithelial cells at different time points after exposure (A) At post-exposure 1 hour, no obvious superficial epithelial sloughing, or increased intercell... by Chun-Ting Lai (791855)

Cytotoxicity assay. by Rodrigo Rollin-Pinheiro (239450)

Pandemic Response Box library screening data. by Rodrigo Rollin-Pinheiro (239450)

Effects of soil microorganisms application to substrates of different organic matter content on Quantum Yield (QY) (A) and Normalized Difference Vegetation Index (NDVI) (B) in toma... by Robert Pokluda (8871407)

Cytotoxicity assay. by Rodrigo Rollin-Pinheiro (239450)

Screening of the Pandemic Response Box^® library. by Rodrigo Rollin-Pinheiro (239450)

Gender-specific incidence trends of HFMD in Guangzhou from 2013 to 2023. by Haipeng Luo (5322419)

Effect of alexidine, amorolfine and olorofim on preformed biofilms of <i>Scedosporium</i> and <i>Lomentospora</i> species. by Rodrigo Rollin-Pinheiro (239450)

Effect of alexidine, amorolfine and olorofim on biofilm formation of <i>Scedosporium</i> and <i>Lomentospora</i> species. by Rodrigo Rollin-Pinheiro (239450)

Period of influence of each daily variable on the pod status change, from healthy to diseased with no signs of sporulation, 40 to 50 days after tagging. by Mariela E. Leandro-Muñoz (4487608)

Immunofluorescence of select extracellular matrix (ECM) components. by Melissa A. MacIver (12850566)

“…<p>Matched sections from traditional histology (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0269571#pone.0269571.g008" target="_blank">Fig 8</a>) were assessed via immunofluorescence for aggrecan, Collagen Type II, and Collagen Type X. …”

The effects of clonidine on mean arterial blood pressure, fluid flux and luminal alkalinisation. by Olof Nylander (599995)

“…<p>Duodenum was perfused with isotonic saline for 90 min and clonidine was administered from 30 min as a constant i.v. infusion at a dose of 10 or 50 μg kg^-1 h^-1 (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0273208#pone.0273208.g001" target="_blank">Fig 1</a>). …”

Standardized mean effect differences between wet-lab experiment and model simulations. by Rachael Miller Neilan (10678614)

“…<p>Hedges’ <i>g</i> standardized mean effect differences were calculated between different groups from our wet-lab experiments and three models (60:40, 50:50, and 30:70) which differed based on the PKC<i>δ</i>:SOM ratio. …”

image2_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.tif by Xin Zhi (1829224)

“…Specifically, myostatin increased the phosphorylation of Smad2, which led to the activation of NF-κB and MAPK pathways to activate osteoclastogenesis. Ccdc50 was identified as a gene whose expression was highly decreased in osteoclastogenesis upon myostatin treatment, and it could inhibit the function of myostatin in osteoclastogenesis by blocking NF-κB and MAPKs pathways. …”

presentation1_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.pptx by Xin Zhi (1829224)

“…Specifically, myostatin increased the phosphorylation of Smad2, which led to the activation of NF-κB and MAPK pathways to activate osteoclastogenesis. Ccdc50 was identified as a gene whose expression was highly decreased in osteoclastogenesis upon myostatin treatment, and it could inhibit the function of myostatin in osteoclastogenesis by blocking NF-κB and MAPKs pathways. …”

image3_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.tif by Xin Zhi (1829224)

“…Specifically, myostatin increased the phosphorylation of Smad2, which led to the activation of NF-κB and MAPK pathways to activate osteoclastogenesis. Ccdc50 was identified as a gene whose expression was highly decreased in osteoclastogenesis upon myostatin treatment, and it could inhibit the function of myostatin in osteoclastogenesis by blocking NF-κB and MAPKs pathways. …”

presentation1_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.pptx by Xin Zhi (1829224)

“…Specifically, myostatin increased the phosphorylation of Smad2, which led to the activation of NF-κB and MAPK pathways to activate osteoclastogenesis. Ccdc50 was identified as a gene whose expression was highly decreased in osteoclastogenesis upon myostatin treatment, and it could inhibit the function of myostatin in osteoclastogenesis by blocking NF-κB and MAPKs pathways. …”

presentation1_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.pptx by Xin Zhi (1829224)

“…Specifically, myostatin increased the phosphorylation of Smad2, which led to the activation of NF-κB and MAPK pathways to activate osteoclastogenesis. Ccdc50 was identified as a gene whose expression was highly decreased in osteoclastogenesis upon myostatin treatment, and it could inhibit the function of myostatin in osteoclastogenesis by blocking NF-κB and MAPKs pathways. …”

image1_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.tif by Xin Zhi (1829224)

“…Specifically, myostatin increased the phosphorylation of Smad2, which led to the activation of NF-κB and MAPK pathways to activate osteoclastogenesis. Ccdc50 was identified as a gene whose expression was highly decreased in osteoclastogenesis upon myostatin treatment, and it could inhibit the function of myostatin in osteoclastogenesis by blocking NF-κB and MAPKs pathways. …”

image1_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.tif by Xin Zhi (1829224)

“…Specifically, myostatin increased the phosphorylation of Smad2, which led to the activation of NF-κB and MAPK pathways to activate osteoclastogenesis. Ccdc50 was identified as a gene whose expression was highly decreased in osteoclastogenesis upon myostatin treatment, and it could inhibit the function of myostatin in osteoclastogenesis by blocking NF-κB and MAPKs pathways. …”